Name: Relias Media
Price range: $

Report Details Effect of Mifepristone Labeling Change

New research indicates that for Texas providers and patients, the 2016 Food and Drug Administration’s (FDA) new labeling for the abortion drug mifepristone increased access options and brought the proportion of medication abortions in the state into alignment with national data.

Test in Development to Detect Preterm Birth

Scientists at Brigham and Women’s Hospital have published early results of an investigative blood test designed to predict which women may be at increased risk and which ones may be at lower-than-average risk for spontaneous preterm delivery. The researchers have identified circulating microparticle proteins found in blood samples taken in the first trimester of pregnancy that may provide clues about the risk of spontaneous preterm birth.

National Plan Aimed at Ending HIV in the United States

The goal of a new national plan is to end the HIV epidemic in the United States.

HPV Immunizations Making Mark on Disease

In a multi-year analysis of cervical precancers, data indicate that the incidence of cancers caused by human papillomavirus (HPV) types 16 and 18, which have been targeted by vaccination, has declined.

Reproductive Health Advocates Push Back Against Proposed Title X Plans

On March 4, the Trump administration published a final regulation that is a new version of the Reagan administration’s “domestic gag rule.” With the rule’s publication in the Federal Register, a 60-day clock is ticking until provisions of the rule start going into effect.

Advanced Research Underway on Potential Copper IUD

Patient enrollment has begun in the United States for Phase III trials of a new copper intrauterine device (IUD) with a flexible frame.

State Policymakers Work Toward and Against a Post-Roe Country

Trial Underway for Vaginal Ring Device Designed for HIV Prevention

Researchers are evaluating a vaginal ring designed to protect women against both HIV and herpes simplex virus type 2 in a Phase I study. The trial is being conducted by researchers from the National Institutes of Health-funded Microbicide Trials Network at three U.S. sites in Alabama, California, and Pennsylvania.